The genomic medicine developer plans to raise up to $100m in an upcoming IPO that could hand exits to Amgen Ventures, Brace Pharma Capital and Baxter Ventures.
Precision BioSciences, a US-based genomic medicine developer backed by pharmaceutical firms Amgen, EMS and Baxter, has filed to raise up to $100m in an initial public offering.
The company plans to float on the Nasdaq Global Market and has appointed JP Morgan, Goldman Sachs, Jefferies and Barclays as joint bookrunners for the IPO.
Spun out of Duke University in 2006, Precision BioSciences has created a genome editing platform dubbed Arcus, which is being used in the development of immuno-oncology and…
